Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;175(3):425-38.
doi: 10.1111/cei.12226.

Multiple sclerosis treatment and infectious issues: update 2013

A Winkelmann  1 , M Loebermann, E C Reisinger, U K Zettl
Affiliations
Review

Multiple sclerosis treatment and infectious issues: update 2013

A Winkelmann et al. Clin Exp Immunol. 2014 Mar.

Abstract

Immunomodulation and immunosuppression are generally linked to an increased risk of infection. In the growing field of new and potent drugs for multiple sclerosis (MS), we review the current data concerning infections and prevention of infectious diseases. This is of importance for recently licensed and future MS treatment options, but also for long-term established therapies for MS. Some of the disease-modifying therapies (DMT) go along with threats of specific severe infections or complications, which require a more intensive long-term monitoring and multi-disciplinary surveillance. We update the existing warning notices and infectious issues which have to be considered using drugs for multiple sclerosis.

Keywords: disease-modifying treatment; immunosuppression; infection; multiple sclerosis; side effects.

PubMed Disclaimer

References

    1. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013 doi: 10.1016/j.jns.2013.05.010. - DOI - PubMed
    1. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–2197. - PMC - PubMed
    1. Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev. 2012;11:167–173. - PubMed
    1. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010;33:140–152. - PubMed
    1. Jeffery DR. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis. 2013;4:45–51. - PMC - PubMed

MeSH terms

Substances